Trending...
- Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs - 128
- $36 Million LOI to Acquire High Value Assets from Vivakor Inc in Oklahoma's STACK Play — Building Cash Flow and Scalable Power Infrastructure; $OLOX
- Off The Hook YS (NY SE: OTH) Executes Transformational Apex Acquisition, Creating Vertically Integrated Marine Powerhouse with $60M Inventory Capacity
Official psychiatric publication acknowledges diagnostic errors and prolonged antidepressant withdrawal—confirming concerns long raised by patients, researchers, and CCHR.
LOS ANGELES - Michimich -- By CCHR International
The Citizens Commission on Human Rights International (CCHR) says a landmark article published in Psychiatric Times confirms what patients, independent researchers, and CCHR have documented and warned about for more than three decades: SSRI antidepressant withdrawal is more common and severe than previously acknowledged and frequently misdiagnosed.[1]
For millions of Americans, this recognition is not new information; it is validation.
Since the introduction of selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and paroxetine in the late 1980s and early 1990s, withdrawal risks have routinely been denied, minimized, or reframed. Patients reporting withdrawal symptoms were often told they were experiencing a relapse of their underlying "mental illness." The recent Psychiatric Times article acknowledges that relapse became a "common diagnostic error," leading to reinstatement of medication and "trapping patients in a cycle of long-term use based on a misunderstanding of their symptoms."
The authors also concede serious methodological flaws in traditional relapse-prevention trials that can inflate perceptions of benefit while obscuring evidence of physiological dependence. They describe the current reassessment of antidepressant withdrawal as a "paradigm shift."
CCHR disputes that characterization.
Jan Eastgate, President of CCHR International, says, "This is not a paradigm shift. It is a belated recognition of a public health crisis that patients have been reporting for decades."
Today, at least 45 million Americans—including approximately 2.1 million children and adolescents—are taking antidepressants. A 2019 systematic review found, using a weighted average, that 56% of patients experienced withdrawal symptoms after stopping antidepressants. That would equate to approximately 25.2 million Americans, including more than one million children and adolescents, who could potentially suffer withdrawal effects when they stop taking the drugs.[2]
More on Michimich.com
Withdrawal effects include dizziness, vertigo, "brain zaps" (electric shock sensations), paresthesia (numbness, tingling, or burning), cognitive impairment, and akathisia, a distressing movement disorder characterized by an uncontrollable, intense urge to move and severe inner restlessness; new or worsening anxiety, irritability, emotional blunting, insomnia, fatigue, and impaired concentration.[3]
CCHR maintains these reactions are not minor inconveniences but destabilizing physiological responses that can impair functioning and, in severe cases, contribute to suicidal or violent behavior.
In 2019, The New York Times reported that physicians had for years "dismissed or downplayed such symptoms," frequently attributing them to recurrence of mood disorders.[4]
CCHR points to what it describes as a strategic and misleading shift in terminology.
In 1996, at a pharmaceutical industry-funded meeting, the term "antidepressant discontinuation syndrome" (ADS) was introduced in place of "withdrawal." In 1997, experts who attended the meeting published papers promoting the new terminology.[5] In 2001, sales representatives for the manufacturer of paroxetine (Paxil) were reportedly instructed to avoid using the word "withdrawal."[6]
Dr. David Healy, a leading psychopharmacologist, has argued that the term was designed to deflect from concerns about dependence. He and colleagues stated: "In lay terms, you can just as easily become hooked on SSRIs as on benzodiazepines or opiates, and SSRIs can be more difficult to get off than anything else."[7]
ADS was added to the APA's Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and remains in the DSM-5-TR as a "medication-related adverse effect." In 2025, an APA member writing in Psychiatric Times described withdrawal as a "very small minority" who experience severe and prolonged symptoms.
CCHR argues that this underscores the scope of a problem long minimized.
Dr. Josef Witt-Doerring, a U.S. psychiatrist specializing in tapering and withdrawal management, has warned that discontinuation can take months and that symptoms may persist for years. Full recovery may take 12 to 24 months. In some cases, he notes, symptoms can drive individuals to suicidal despair.[8]
More on Michimich.com
Despite mounting evidence, U.S. antidepressant labels mention discontinuation symptoms but portray them as short-lived and, as Josef Witt-Doerring has noted, do not warn of months-long withdrawal.
CCHR says the recent acknowledgment in Psychiatric Times represents a long overdue validation for millions who were told their suffering was imaginary, exaggerated, or evidence of relapse. "For 36 years, CCHR has documented patient testimonies, regulatory failures, and industry tactics that minimized the risks of antidepressant withdrawal," Eastgate stated.
CCHR, which was established by the Church of Scientology and Professor of psychiatry Thomas Szasz in 1969, says the FDA now needs to solve this problem and take decisive corrective action proportionate to the scale of harm. Until resolved, there must be immediate label revisions clearly warning of severe and protracted withdrawal and the creation of a national adverse-event reporting database dedicated specifically to psychiatric drugs, with mandatory reporting of suicides, violence, and severe or prolonged withdrawal reactions.
Until the FDA and the APA fully confront and correct a crisis that developed under their authority, millions remain at risk. The FDA approved these drugs and allowed labeling that minimized dependence and withdrawal risks. Eastgate adds, "The oversight of agencies entrusted to protect Americans has failed. Recognition in a journal is not reform. Acknowledgment is not accountability."
Sources:
[1] Nicolas Badre, MD, et al., "Exiting Antidepressants: A Needed Spotlight on Withdrawal," Psychiatric Times, 9 Feb. 2026
[2] James Davies and John Read, "A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?" Addictive Behaviors, 97 (2019), p. 111
[3] Nicolas Badre, MD, Psychiatric Times, 9 Feb. 2026
[4] Christopher Lane, Ph.D., "Antidepressant Guidelines to Tighten in the UK: Welcome policy change also reveals scale of the problem," Psychology Today, 31 May 2019; Benedict Carey, "How to Quit Antidepressants: Very Slowly, Doctors Say," The New York Times, 5 Mar. 2019
[5] Joseph Glenmullen, M.D., Prozac Backlash, (Simon & Schuster, NY, 2000), p. 76
[6] "Drug Maker Withheld Paxil Study Data," ABC News, 9 Dec. 2004, https://abcnews.com/Health/story?id=311956
[7] David Healy, et al., Children of the Cure: Missing Data, Lost Lives and Antidepressants, (Samizdat Health Writer's Co-operative Inc., 2020), pp. 43-44
[8] "SSRI Dangers & Tapering Off Safely with Dr. Josef Witt-Doerring," Independent Medical Alliance, 11 Sept. 2025
The Citizens Commission on Human Rights International (CCHR) says a landmark article published in Psychiatric Times confirms what patients, independent researchers, and CCHR have documented and warned about for more than three decades: SSRI antidepressant withdrawal is more common and severe than previously acknowledged and frequently misdiagnosed.[1]
For millions of Americans, this recognition is not new information; it is validation.
Since the introduction of selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and paroxetine in the late 1980s and early 1990s, withdrawal risks have routinely been denied, minimized, or reframed. Patients reporting withdrawal symptoms were often told they were experiencing a relapse of their underlying "mental illness." The recent Psychiatric Times article acknowledges that relapse became a "common diagnostic error," leading to reinstatement of medication and "trapping patients in a cycle of long-term use based on a misunderstanding of their symptoms."
The authors also concede serious methodological flaws in traditional relapse-prevention trials that can inflate perceptions of benefit while obscuring evidence of physiological dependence. They describe the current reassessment of antidepressant withdrawal as a "paradigm shift."
CCHR disputes that characterization.
Jan Eastgate, President of CCHR International, says, "This is not a paradigm shift. It is a belated recognition of a public health crisis that patients have been reporting for decades."
Today, at least 45 million Americans—including approximately 2.1 million children and adolescents—are taking antidepressants. A 2019 systematic review found, using a weighted average, that 56% of patients experienced withdrawal symptoms after stopping antidepressants. That would equate to approximately 25.2 million Americans, including more than one million children and adolescents, who could potentially suffer withdrawal effects when they stop taking the drugs.[2]
More on Michimich.com
- Rocket Fibre Services Growing Customer Base With netElastic Networking Software
- Cummings Graduate Institute for Behavioral Health Studies Honors New Doctor of Behavioral Health Graduates
- IDpack v4 Launches: A Major Evolution in Cloud-Based ID Card Issuance
- 505 Plumbing, Heating & Cooling Launches in Albuquerque, Bringing a Customer-First Approach to Home Services
- As AI.com Sells For Record $70 Million, Attention Now Turns To ArtificialIntelligence.com
Withdrawal effects include dizziness, vertigo, "brain zaps" (electric shock sensations), paresthesia (numbness, tingling, or burning), cognitive impairment, and akathisia, a distressing movement disorder characterized by an uncontrollable, intense urge to move and severe inner restlessness; new or worsening anxiety, irritability, emotional blunting, insomnia, fatigue, and impaired concentration.[3]
CCHR maintains these reactions are not minor inconveniences but destabilizing physiological responses that can impair functioning and, in severe cases, contribute to suicidal or violent behavior.
In 2019, The New York Times reported that physicians had for years "dismissed or downplayed such symptoms," frequently attributing them to recurrence of mood disorders.[4]
CCHR points to what it describes as a strategic and misleading shift in terminology.
In 1996, at a pharmaceutical industry-funded meeting, the term "antidepressant discontinuation syndrome" (ADS) was introduced in place of "withdrawal." In 1997, experts who attended the meeting published papers promoting the new terminology.[5] In 2001, sales representatives for the manufacturer of paroxetine (Paxil) were reportedly instructed to avoid using the word "withdrawal."[6]
Dr. David Healy, a leading psychopharmacologist, has argued that the term was designed to deflect from concerns about dependence. He and colleagues stated: "In lay terms, you can just as easily become hooked on SSRIs as on benzodiazepines or opiates, and SSRIs can be more difficult to get off than anything else."[7]
ADS was added to the APA's Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and remains in the DSM-5-TR as a "medication-related adverse effect." In 2025, an APA member writing in Psychiatric Times described withdrawal as a "very small minority" who experience severe and prolonged symptoms.
CCHR argues that this underscores the scope of a problem long minimized.
Dr. Josef Witt-Doerring, a U.S. psychiatrist specializing in tapering and withdrawal management, has warned that discontinuation can take months and that symptoms may persist for years. Full recovery may take 12 to 24 months. In some cases, he notes, symptoms can drive individuals to suicidal despair.[8]
More on Michimich.com
- AOW Event Sponsored By The Stanglwirt Resort a renowned five-star Austrian wellness destination
- Average US gambler spends $210 per month in 2026
- 10X Recruitment Launches Operator-Led Executive Search for Behavioral Health and Legal Leaders
- Integris Composites developing armor for military in Arctic Circle
- Caraline Skincare's Gentle Glow Cleansing Oil Named Finalist for Best Face Cleanser at the 2026 CertClean Clean Beauty Awards
Despite mounting evidence, U.S. antidepressant labels mention discontinuation symptoms but portray them as short-lived and, as Josef Witt-Doerring has noted, do not warn of months-long withdrawal.
CCHR says the recent acknowledgment in Psychiatric Times represents a long overdue validation for millions who were told their suffering was imaginary, exaggerated, or evidence of relapse. "For 36 years, CCHR has documented patient testimonies, regulatory failures, and industry tactics that minimized the risks of antidepressant withdrawal," Eastgate stated.
CCHR, which was established by the Church of Scientology and Professor of psychiatry Thomas Szasz in 1969, says the FDA now needs to solve this problem and take decisive corrective action proportionate to the scale of harm. Until resolved, there must be immediate label revisions clearly warning of severe and protracted withdrawal and the creation of a national adverse-event reporting database dedicated specifically to psychiatric drugs, with mandatory reporting of suicides, violence, and severe or prolonged withdrawal reactions.
Until the FDA and the APA fully confront and correct a crisis that developed under their authority, millions remain at risk. The FDA approved these drugs and allowed labeling that minimized dependence and withdrawal risks. Eastgate adds, "The oversight of agencies entrusted to protect Americans has failed. Recognition in a journal is not reform. Acknowledgment is not accountability."
Sources:
[1] Nicolas Badre, MD, et al., "Exiting Antidepressants: A Needed Spotlight on Withdrawal," Psychiatric Times, 9 Feb. 2026
[2] James Davies and John Read, "A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?" Addictive Behaviors, 97 (2019), p. 111
[3] Nicolas Badre, MD, Psychiatric Times, 9 Feb. 2026
[4] Christopher Lane, Ph.D., "Antidepressant Guidelines to Tighten in the UK: Welcome policy change also reveals scale of the problem," Psychology Today, 31 May 2019; Benedict Carey, "How to Quit Antidepressants: Very Slowly, Doctors Say," The New York Times, 5 Mar. 2019
[5] Joseph Glenmullen, M.D., Prozac Backlash, (Simon & Schuster, NY, 2000), p. 76
[6] "Drug Maker Withheld Paxil Study Data," ABC News, 9 Dec. 2004, https://abcnews.com/Health/story?id=311956
[7] David Healy, et al., Children of the Cure: Missing Data, Lost Lives and Antidepressants, (Samizdat Health Writer's Co-operative Inc., 2020), pp. 43-44
[8] "SSRI Dangers & Tapering Off Safely with Dr. Josef Witt-Doerring," Independent Medical Alliance, 11 Sept. 2025
Source: Citizens Commission on Human Rights International
0 Comments
Latest on Michimich.com
- Why One American Manufacturer Builds BBQ Smokers to Aerospace Standards
- Diversified Roofing Solutions Strengthens Industry Leadership With Expanded Roofing Services Across South Florida
- ZRCalc™ Cinema Card Calculator Now Available for Nikon ZR Shooters
- Revolutionary Data Solution Transforms Health Insurance Underwriting Accuracy
- $36 Million LOI to Acquire High Value Assets from Vivakor Inc in Oklahoma's STACK Play — Building Cash Flow and Scalable Power Infrastructure; $OLOX
- Kobie Wins for AI Innovations in the 2026 Stevie® Awards for Sales & Customer Service
- Berman | Sobin | Gross LLP Celebrates 35 Years of Advocating for Maryland's Injured Workers and Families
- Art of Whiskey Hosts 3rd Annual San Francisco Tasting Experience During Super Bowl Week
- Novi Custom Glass Manufacturer Explains Why Custom Glass Doors Beat Off-the-Shelf
- PADT Earns Prestigious 2025 Americas Customer Loyalty Award from Ansys, Part of Synopsys
- Florida Keys Visitors Can Save 15 Percent With KeysCaribbean's Advanced Booking Discount
- Detroit Homeowners Facing Property Tax Foreclosure Explore Options to Sell Before Losing Their Homes
- Sleep Basil Unveils Revamped Natural Latex Mattress Collection Page for Cooler, Cleaner, Better-Aligned Sleep
- Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
- Sterling Heights to Hold Public Meeting on Proposed Property Acquisition Across from Rotary Park
- Sterling Heights: Looking Local: Maria Aldana Builds Raíces on Heritage, Perseverance and Flavor
- CIMdata to Host a Webinar Introducing a Framework for Understanding AI Implementations in PLM
- AAACF Inspires Leaders to Grow in Washtenaw Co. at the A2Y Regional Chamber All In Workforce Development & Organizational Planning Program
- FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
- $2.7 Million 2025 Revenue; All Time Record Sales Growth; 6 Profitable Quarters for Homebuilding Industry: Innovative Designs (Stock Symbol: IVDN)